ERBB2 and neoplasm: For example, recent studies have shown that PIK3CA mutations are associated with different outcomes in breast cancer depending on whether the tumor is estrogen receptor positive or negative, and whether HER2 is over-expressed or amplified compared to HER2-normal [22], [23].